Breakthrough in Regenerative Medicine: Japan Approves World's First iPS Cell Therapies
Innovative regenerative medicine technology has entered a new phase. On February 19, 2026, an expert panel of the Ministry of Health, Labour and Welfare (MHLW) approved, for the first time in the world, conditional and time-limited manufacturing and marketing authorization for two types of regenerative medicine products using iPS cells (induced pluripotent stem cells). This marks the practical realization of iPS cell technology, which has been under research for many years, opening new avenues of treatment for patients suffering from severe heart disease and Parkinson's disease. The approved products are 'ReHeart,' a myocardial cell sheet for severe heart failure developed by Qualips Inc., and 'Amschepur,' cells for brain transplantation aimed at treating Parkinson's disease, developed by Sumitomo Pharma. These products are created by differentiating iPS cells, aiming to regenerate lost tissues and functions. iPS cells were developed by Professor Shinya Yamanaka...